You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,383,950


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,383,950
Title:Methods and compositions of carrier systems for the purpose of intracellular drug targeting
Abstract: The present invention relates to a carrier system, a carrier and a pharmaceutical composition comprising a pathogen entry protein or fragment thereof, which specifically binds to a molecule on the surface of a mammalian target cell of said pathogen and which is covalently linked to the surface of said carrier and at least one hydrophilic antipathogenic agent. It further relates to a method of manufacturing a carrier system and the carrier system or the pharmaceutical composition for the use as a medicament.
Inventor(s): Lehr; Claus-Michael (Saarbrucken-Dudweiler, DE), Labouta; Hagar Ibrahim (Calgary, CA), Gordon; Sarah (Saarbrucken, DE), Castoldi; Arianna (Saarbrucken, DE), Menina; Sara (Homburg Saar, DE), Geyer; Rebecca (Braunschweig, DE), Kochut; Annika (Braunschweig, DE), Dersch; Petra (Hannover, DE)
Assignee: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE/DE) (Braunschweig, DE)
Application Number:15/503,010
Patent Claims:1. A carrier system, comprising (i) a carrier, (ii) a pathogen entry protein or fragment thereof, which specifically binds to a molecule on the surface of a mammalian target cell of said pathogen and which is covalently linked to the surface of said carrier, and (iii) at least one hydrophilic antipathogenic agent, wherein the pathogen entry protein specifically binds to the extracellular domain of .beta..sub.1-integrin receptor, and the pathogen entry protein is not SEQ ID NO:6.

2. The carrier system according to claim 1, wherein said carrier is selected from the group consisting of nanoparticles, preferably matrices of solid-lipid nanoparticles (SLN); polymer particles, preferably nanocapsules; vesicles, preferably liposomes and other artificially-prepared spherical or non-- spherical vesicles.

3. The carrier system according to claim 2, wherein the liposome is unilamellar or multilamellar and/or the overall charge of the liposome is positive, neutral or negative.

4. The carrier system according to claim 1, wherein the molecule on the surface of a mammalian target cell is a receptor protein, preferably a .beta..sub.1-integrin receptor.

5. The carrier system according to claim 1 wherein the pathogen entry protein is from a bacterium that sequesters in a non-phagocytic cell.

6. The carrier system according to claim 5, wherein the bacterium is a Gram-negative bacterium, preferably Chlamydia, Coxiella burnetii, Ehrlichia, Rickettsia, Legionella, Salmonella, Shigella, or Yersinia; or a Gram-positive bacterium, preferably Mycobacterium leprae, or Mycobacterium tuberculosis, more preferably Yersinia.

7. The carrier system according to claim 5, wherein the pathogen entry protein is selected from the group consisting of invasin, Yersinia adhesin A (YadA), internalin and other inv-type and related adhesive bacterial outer membrane molecules.

8. The carrier system according to claim 1, wherein the covalent link between the carrier and the pathogen entry protein is direct or via a linker.

9. The carrier system according to claim 1, wherein the pathogen entry protein is linked via its C-terminus, its N-terminus or a side chain of an amino acid of said pathogen entry protein, preferably its N-terminus.

10. The carrier system according to claim 7, wherein the invasin has an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or variants thereof with at least 70% amino acid sequence identity and which specifically bind to the extracellular domain of .beta..sub.1-integrin receptor.

11. The carrier system according to claim 1, wherein the fragment of the pathogen entry protein consists or essentially consists of the extracellular domain of pathogen entry protein.

12. The carrier system according to claim 11, wherein the hydrophilic antipathogenic agent is selected from the group consisting of small molecules; proteins; nucleic acids, preferably siRNA; nucleotides, preferably polynucleotides.

13. The carrier system according to claim 12, wherein the hydrophilic antipathogenic agent is an antibiotic or cytostatic.

14. The carrier according to claim 13, wherein (i) the antibiotic is selected from the group consisting of polypeptides, glycopeptides, aminoglycosides, lipopeptides, quinolones or .beta.-lactam antibiotics and organic or anorganic salts thereof, (ii) the cytostatic is selected from the group consisting of alkylating substances, anti-metabolites, epothilones, nuclear receptor agonists and antagonists, anti-androgens, anti-estrogens, platinum compounds, hormones and antihormones, interferons and inhibitors of cell cycle-dependent protein kinases (CDKs), inhibitors of cyclooxygenases and/or lipoxygenases, biogenic fatty acids and fatty acid derivatives, including prostanoids and leukotrienes, inhibitors of protein kinases, inhibitors of protein phosphatases, inhibitors of lipid kinases, platinum coordination complexes, ethyleneamines, methylmelamines, trazines, vinca alkaloids, pyrimidine analogs, purine analogs, alkylsulfonates, folic acid analogs, anthracendiones, substituted urea, methylhydrazine derivatives, in particular acediasulfone, aclarubicine, ambazone, aminoglutethimide, L-asparaginase, azathioprine, bleomycin, busulfan, calcium folinate, carboplatin, carpecitabine, carmustine, celecoxib, chlorambucil, cis-platin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dapsone, daunorubicin, dibrompropamidine, diethylstilbestrol, docetaxel, doxorubicin, enediynes, epirubicin, epothilone B, epothilone D, estramucin phosphate, estrogen, ethinylestradiol, etoposide, flavopiridol, floxuridine, fludarabine, fluorouracil, fluoxymesterone, flutamide, fosfestrol, furazolidone, gemcitabine, gonadotropin releasing hormone analog, hexamethylmelamine, hydroxycarbamide, hydroxymethylnitrofurantoin, hydroxyprogesteronecaproate, hydroxyurea, idarubicin, idoxuridine, ifosfamide, interferon .alpha., irinotecan, leuprolide, lomustine, lurtotecan, mafenide sulfate olamide, mechlorethamine, medroxyprogesterone acetate, megastrol acetate, melphalan, mepacrine, mercaptopurine, methotrexate, metronidazole, mitomycin C, mitopodozide, mitotane, mitoxantrone, mithramycin, nalidixic acid, nifuratel, nifuroxazide, nifuralazine, nifurtimox, nimustine, ninorazole, nitrofurantoin, nitrogen mustards, oleomucin, oxolinic acid, pentamidine, pentostatin, phenazopyridine, phthalylsulfathiazole, pipobroman, prednimustine, prednisone, preussin, procarbazine, pyrimethamine, raltitrexed, rapamycin, rofecoxib, rosiglitazone, salazosulfapyridine, scriflavinium chloride, semustine, streptozocin, sulfacarbamide, sulfacetamide, sulfachlopyridazine, sulfadiazine, sulfadicramide, sulfadimethoxine, sulfaethidole, sulfafurazole, sulfaguanidine, sulfaguanole, sulfamethizole, sulfamethoxydiazine, sulfamethoxypyridazine, sulfamoxole, sulfanilamide, sulfaperin, sulfaphenazole, sulfathiazole, sulfisomidine, staurosporin, tamoxifen, taxol, tenipo side, tertipo side, testolactone, testosterone propionate, thioguanine, thiotepa, tinidazole, topotecan, triaziquone, treosulfan, trimethoprim, trofosfamide, UCN-01, vinblastine, vincristine, vindesine, vinblastine, vinorelbine, and zorubicin and organic or anorganic salts thereof.

15. A carrier system according to claim 1, wherein the hydrophilic antipathogenic agent exhibits a variable release kinetic from the carrier system.

16. A pharmaceutical composition comprising a carrier system according to claim 1 and a pharmaceutical acceptable excipient.

17. A pharmaceutical composition according to claim 16, wherein the carrier system is released from the pharmaceutical composition with a variable release kinetic.

18. A pharmaceutical according to claim 17, wherein the release kinetic is selected from the group of rapid release kinetics, sustained release kinetics or delayed release kinetics.

19. A method of manufacturing a carrier system according to claim 1, comprising the step of covalently linking the pathogen entry protein or part thereof to the carrier either prior or after contacting the carrier with at least one hydrophilic antipathogenic agent.

20. The method of claim 19, wherein the pathogen entry protein and/or at least one constituent of the carrier comprises an activatable group prior to covalent linking.

21. The method of claim 20, wherein the activatable group is activated with an activating reagent selected from the group consisting of carbodiimides, preferably N,N'-diisopropylcarbodiimide (DIC), N,N'-dicyclohexylcarbodiimide (DCC), more preferably N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC); succinimidylesters, preferably sulfosuccinimide, N-hydroxybenzotriazole, more preferably N-hydroxysuccinimid (NHS); triazine-based coupling reagents, preferably 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholiniumchloride (DMTMM); maleidesters; and glutaraldehyde.

22. The method of claim 21, wherein the activating reagent is a mixture of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), preferably EDC in a concentration of 5-100 mM, preferably 48 mM and NHS in a molar concentration range of 1-50 mM, preferably 19 mM.

23. Carrier system according to claim 1 for use as medicament.

24. Carrier system according to claim 1 for the treatment or prophylaxis of infectious diseases, preferably systemic infection.

25. Carrier system according to claim 24, wherein the infectious disease is an infection with a bacterium that sequesters in a non-phagocytic cells, preferably a Gram-negative bacterium, more preferably Chlamydia, Coxiella burnetii, Ehrlichia, Rickettsia, Legionella, Salmonella, Shigella, or Yersinia; or Gram-positive bacterium, more preferably Mycobacterium leprae, or Mycobacterium tuberculosis.

26. The carrier system according to claim 1, wherein the pathogen entry protein is YadA, preferably having SEQ ID NO: 8 or SEQ ID NO: 9, or a variant thereof with at least 70% amino acid sequence identity and which specifically binds to the extracellular domain of .beta..sub.1-integrin receptor.

27. The carrier system according to claim 1, wherein the pathogen entry protein comprises an amino acid sequence consisting of amino acids 191 to 289 of SEQ ID NO:2.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.